Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours

BMC Veterinary Research

John A. Hartley¹  Anneliese Stell⁴  Stephen J. Baines³  David E. Thurston²  R. Barbara Pedley⁵  Matthew Robson⁵  Solange R. Paredes-Moscosso¹  Victoria J. Spanswick¹  Maria Mellinas-Gomez⁴ 

[1] CR-UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O’Gorman Building, University College London, 72 Huntley Street, London WC1E 6BT, UK;Present address: Institute of Pharmaceutical Science, King’s College London, Britannia House, 7 Trinity Street, London SE1 1DB, UK;Present address: Willows Referral Service, Highlands Road, Shirley, Solihull, West Midlands B90 4NH, UK;Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, Herts AL9 7TA, UK;UCL Cancer Institute, Paul O’Gorman Building, 72 Huntley Street, London WC1E 6BT, UK

关键词: Cancer chemotherapy;    Pyrrolobenzodiazepine dimer;    Anticancer drug;    DNA interstrand cross-linking;    SG2000 (SJG-136);    Canine cancer;   

Others  :  1224307
DOI  :  10.1186/s12917-015-0534-2

 received in 2015-01-09, accepted in 2015-08-06,  发布年份 2015

【 摘 要 】

Background

Cancer is the leading cause of death in older dogs and its prevalence is increasing. There is clearly a need to develop more effective anti-cancer drugs in dogs. SG2000 (SJG-136) is a sequence selective DNA minor groove cross-linking agent. Based on its in vitro potency, the spectrum of in vivo and clinical activity against human tumours, and its tolerability in human patients, SG2000 has potential as a novel therapeutic against spontaneously occurring canine malignancies.

Results

In vitro cytotoxicity was assessed using SRB and MTT assays, and in vivo activity was assessed using canine tumour xenografts. DNA interstrand cross-linking (ICL) was determined using a modification of the single cell gel electrophoresis (comet) assay. Effects on cell cycle distribution were assessed by flow cytometry and measurement of γ-H2AX by immunofluorescence and immunohistochemistry.

SG2000 had a multi-log differential cytotoxic profile against a panel of 12 canine tumour cell lines representing a range of common tumour types in dogs. In the CMeC-1 melanoma cell line, DNA ICLs increased linearly with dose following a 1 h treatment. Peak ICL was achieved within 1 h and no removal was observed over 48 h. A relationship between DNA ICL formation and cytotoxicity was observed across cell lines. The formation of γ-H2AX foci was slow, becoming evident after 4 h and reaching a peak at 24 h.

SG2000 exhibited significant anti-tumour activity against two canine melanoma tumour models in vivo. Anti-tumour activity was observed at 0.15 and 0.3 mg/kg given i.v. either once, or weekly x 3. Dose-dependent DNA ICL was observed in tumours (and to a lower level in peripheral blood mononuclear cells) at 2 h and persisted at 24 h. ICL increased following the second and third doses in a repeated dose schedule. At 24 h, dose dependent γ-H2AX foci were more numerous than at 2 h, and greater in tumours than in peripheral blood mononuclear cells. SG2000-induced H2AX phosphorylation measured by immunohistochemistry showed good correspondence, but less sensitivity, than measurement of foci.

Conclusions

SG2000 displayed potent activity in vitro against canine cancer cell lines as a result of the formation and persistence of DNA ICLs. SG2000 also had significant in vivo antitumour activity against canine melanoma xenografts, and the comet and γ-H2AX foci methods were relevant pharmacodynamic assays. The clinical testing of SG2000 against spontaneous canine cancer is warranted.

【 授权许可】

   
2015 Mellinas-Gomez et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

Fig. 7.

Fig. 8.

【 参考文献 】

• [1]Bronson RT. Variation in age at death of dogs of different sexes and breeds. Am J Vet Res. 1982; 43:2057-9.
• [2]Olson PN. Using the canine genome to cure cancer and other diseases. Theriogenology. 2007; 68:378-81.
• [3]Dobson JM, Samuel S, Milstein H, Rogers K, Wood JLN. Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. J Small Anim Pract. 2006; 43:240-6.
• [4]Hartley JA. The development of pyrrolobenzodiazepines as antitumor agents. Expert Opin Investig Drugs. 2011; 20:733-44.
• [5]Gregson SJ, Howard PW, Hartley JA, Brooks NA, Adams LJ, Jenkins TC et al.. Design synthesis and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. J Med Chem. 2001; 44:737-48.
• [6]Martin C, Ellis T, McGurk CJ, Jenkins TC, Hartley JA, Waring MJ et al.. Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: footprinting and enzyme inhibition studies. Biogeosciences. 2005; 44:4135-47.
• [7]Hartley JA, Spanswick VJ, Brooks N, Clingen PH, McHugh PJ, Hochhauser D et al.. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: Part 1: Cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res. 2004; 64:6693-9.
• [8]Rahman KM, Thompson AS, James CH, Narayanaswamy M, Thurston DE. The pyrrolobenzodiazepine dimer SJG-136 forms sequence-dependent intrastrand cross-links and monoalkylated adducts in addition to interstrand cross-links. J Am Chem Soc. 2009; 131:13756-66.
• [9]Rahman KM, James CH, Thurston DE. Effect of base sequence on the DNA cross-linking properties of pyrrolobenzodiazepine (PBD) dimers. Nucleic Acids Res. 2011; 39:1-13.
• [10]Alley MC, Hollingshead MG, Pacula-Cox CM, Waud WR, Hartley JA, Howard PW et al.. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumour activity: Part 2: Efficacy evaluations. Cancer Res. 2004; 64:6700-6.
• [11]Reid JM, Buhrow SA, Kuffel MJ, Jia L, Spanswick VJ, Hartley JA et al.. Pharmacokinetic, pharmacodynamic and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats. Cancer Chemother Pharmacol. 2011; 68:777-86.
• [12]Buhrow SA, Reid JM, Jia L, McGovern RM, Covey JM, Kobs DJ et al.. LC-MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501). J Chromatogr B Analyt Technol Biomed Life Sci. 2006; 840:56-62.
• [13]Hochhauser D, Meyer T, Spanswick VJ, Wu J, Clingen PH, Loadman P et al.. Phase 1 study of a sequence selective minor groove DNA binding agent (SJG-136) with pharmacokinetic and pharmacodynamic measurements in patients with advanced solid tumors. Clin Cancer Res. 2009; 15:2140-7.
• [14]Puzanov I, Lee W, Chen AP, Calcutt MW, Hachey DL, Vermeulen WL et al.. Phase I, pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Clin Cancer Res. 2011; 17:3794-802.
• [15]Janjigian YY, Lee W, Kris MG, Miller VA, Krug LM, Azzoli CG et al.. A phase I trial of SJG-136 (NSC694501) in advanced solid tumors. Cancer Chemother Pharmacol. 2010; 65:833-8.
• [16]Inoue K, Ohashi E, Kadosawa T, Hong SH, Matsunaga S, Mochizuki M et al.. Establishment and characterisation of four canine melanoma cell lines. J Vet Med Sci. 2004; 66:1437-44.
• [17]Thamm DH, Dickerson EB, Akhtar N, Lewis R, Auerbach R, Helford SC et al.. Biological and molecular characterization of a canine hemangiosarcoma-derived cell line. Res in Vet Sci. 2006; 81:76-86.
• [18]Kent MS, Collins CJ, Ye F. Activation of the AKT and mammalian target of rapamycin pathways and the inhibitory effects of rapamycin on those pathways in canine malignant melanoma cell lines. Am J Vet Res. 2009; 70:263-9.
• [19]Spanswick VJ, Hartley JM, Hartley JA. Measurement of DNA interstrand crosslinking in individual cells using the single cell gel electrophoresis (comet) assay. In: Methods in Molecular Biology, Vol 613 Drug-DNA Interaction Protocols. 2nd ed. Humana Press, Totowa, NJ; 2010: p.267-82.
• [20]Olive PL, Banath JP, Durand RE. Heterogeneity in radiation-induced DNA damage and repair in tumour and normal cells measured using the “comet” assay. Radiat Res. 1990; 122:86-94.
• [21]Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ et al.. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010; 102:1555-77.
• [22]Looney WB, Mayo AA, Allen PM, Morrow JY, Morris HP. A mathematical evaluation of tumour growth curves in rapid, intermediate and slow growing rat hepatomata. Br J Cancer. 1973; 27:341-4.
• [23]Arnould S, Spanswick VJ, Macpherson JS, Hartley JA, Thurston DE, Jodrell DI et al.. Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling. Mol Cancer Ther. 2006; 5:1602-9.
• [24]Clingen PH, Wu JY, Miller J, Mistry N, Chin F, Wynne P, Prise KM et al.. Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem Pharmacol. 2008; 76:19-27.
• [25]Wu J, Clingen PH, Spanswick VJ, Mellinas-Gomez M, Meyer T, Puzanov I et al.. γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from two Phase I clinical trials of SJG-136 (SG2000). Clin Cancer Res. 2013; 19:721-30.
• [26]Bergman PJ. Canine Oral Melanoma. Clin Tech Small Anim Pract. 2007; 2:55-60.
• [27]Femke H, Arjan G. Tumour vascularisation: sprouting angiogenesis and beyond. Cancer Metastasis Rev. 2007; 3:489-502.
• [28]Roizin-Towle L, Hall EJ. Studies with bleomycin and misonidazole on aerated and hypoxic cells. Br J Cancer. 1978; 37:254.
• [29]Banath JP, MacPhail SH, Olive PL. Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines. Cancer Res. 2004; 64:7144-9.
• [30]Sedelnikova OA, Bonner WM. γH2AX in Cancer Cells:A potential biomarker for cancer diagnostics, prediction and recurrence. Cell Cycle. 2006; 5:2909-13.